IP Library Granted Patent US 7,402,657
Granted Patent B2
US 7,402,657 · App. 11/216,610 · Granted Jul 22, 2008

C-C chemokine receptor 3 proteins

Assignee: Millennium Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,402,657
App. No.
11/216,610
Granted
Jul 22, 2008
Kind
B2
Abstract

The present invention relates to isolated and/or recombinant C-C Chemokine Receptor 3 (CKR-3, CCR3) proteins or polypeptides.

Claims (16)

1. An isolated polypeptide comprising a mammalian C-C chemokine receptor 3 protein (CCR3), wherein said CCR3 has at least about 95% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6, and said CCR3 binds a ligand selected from the group consisting of RANTES and MCP-3.

2. The isolated polypeptide of claim 1 , wherein said CCR3 mediates signaling, a cellular response, or signaling and a cellular response upon binding said ligand, wherein said signaling is activation of a G protein or a rapid and transient increase in the concentration of cytosolic free calcium ([Ca 2+ ] i ), and said cellular response is chemotaxis, exocytosis, inflammatory mediator release or integrin activation.

3. The isolated polypeptide of claim 1 , wherein the amino acid sequence of said CCR3 is SEQ ID NO:2.

4. The isolated polypeptide of claim 1 , wherein the amino acid sequence of said CCR3 is SEQ ID NO:6.

5. The isolated polypeptide of claim 1 , wherein said isolated polypeptide is a fusion protein.

6. An isolated polypeptide comprising a mammalian C-C chemokine receptor 3 protein (CCR3), wherein said CCR3 has at least about 95% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6, and said CCR3 binds eotaxin.

7. The isolated polypeptide of claim 6 , wherein said CCR3 mediates signaling, a cellular response, or signaling and a cellular response upon binding eotaxin, wherein said signaling is activation of a G protein or a rapid and transient increase in the concentration of cytosolic free calcium ([Ca 2+ ] i ), and said cellular response is chemotaxis, exocytosis, inflammatory mediator release or integrin activation.

8. The isolated polypeptide of claim 6 , wherein the amino acid sequence of said CCR3 is SEQ ID NO:2.

9. The isolated polypeptide of claim 6 , wherein the amino acid sequence of said CCR3 is SEQ ID NO:6.

10. The isolated polypeptide of claim 6 , wherein said isolated polypeptide is a fusion protein.

11. An isolated polypeptide comprising a C-C chemokine receptor 3 protein (CCR3), wherein the amino acid sequence of said CCR3 protein is selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:6.

12. The isolated polypeptide comprising a C-C chemokine receptor 3 protein (CCR3) of claim 11 , wherein the amino acid sequence of said CCR3 protein consists of SEQ ID NO:2.

13. An isolated polypeptide comprising a mammalian C-C chemokine receptor 3 protein (CCR3) encoded by SEQ ID NO:1.

14. An isolated polypeptide comprising a mammalian C-C chemokine receptor 3 protein (CCR3) encoded by SEQ ID NO:5.

15. The isolated polypeptide of claim 13 , wherein said isolated polypeptide is a fusion protein.

16. The isolated polypeptide of claim 14 , wherein said isolated polypeptide is a fusion protein.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 31, 2018
From: CHILDREN'S HOSPITAL BOSTON
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 046280/0084 →
CONFIRMATORY LICENSE Recorded May 13, 2009
From: CHILDREN'S HOSPITAL (BOSTON)
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 022678/0042 →
Continuity (5)
Continuation 0896365600 · Nov 3, 1997
Division 0872056500 · Sep 30, 1996
Continuation In Part PCTUS960060800 · Jan 19, 1996
Continuation In Part 0837519900 · Jan 19, 1995
Related Publication 20060002926A1 · Jan 5, 2006